Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The highly competitive Cancer Research UK Centre awards recognise the UK’s most innovative, high-impact cancer research and NHS-University collaborations. This coveted funding, announced on Monday, will see £11 million invested in Oxford and the Thames Valley’s cancer research and translational infrastructure, and a further £3 million into training over the next 5 years.

Cancer remains the second largest cause of global mortality, impacting the lives of millions worldwide. Half of us will be diagnosed with cancer, and there is a strong demand for investment in academic excellence, and to support partnerships with industry and public health organisations.

Within Oxford, the funding will draw together academics and experts from across its fundamental, translational and clinical research communities including from cancer doctors, mathematicians, computer & data scientists, vaccinologists, immunologists, cellular biologists, drug discovery experts, clinical trialists, imaging experts and public health specialists. Nationally and internationally, the new investment will foster a multisectoral approach and invest partnerships that will deliver short and long term patient benefit.

 

Nomination as a Centre of Excellence by CRUK is a strong endorsement of the quality and potential of the cancer research offered by Oxford clinicians and academics. Our researchers are working across divisions, departments and disciplines to deliver effective solutions to detecting and treating cancer.
- Professor Tim Elliott, co-Director of the Oxford Cancer network

This CRUK funding will knit together world class research and clinical expertise to deliver earlier, better and safer treatments. Our Centre will support and grow local partnerships with NHS organisations, such as the Oxford University Hospitals NHS Foundation Trust, the Thames Valley Cancer Alliance and the Berkshire West, Oxfordshire and Buckinghamshire Clinical Commissioning Groups. It will strengthen relationships further afield, for example with the Centre in Scotland, with whom we look forward to working closely with in the coming years.
- Professor Mark Middleton, co-Director of the Oxford Cancer network

CRUK remains the key funder for cancer research and its support will help Oxford deliver an integrated program bringing together healthcare providers, basic and clinical research scientists and industry. The support from CRUK is crucial for us to deliver this agenda and will in the end create opportunities for us to develop new therapies and diagnostics in cancer.
- Professor Sir John Bell, Regius Professor of Medicine at Oxford University

The £11 million award for the CRUK Oxford Centre is overseen by Oxford Cancer, the University’s cancer research network. Money will be invested in Oxford’s key themes:

  • Cancer early detection – striving to achieve NHS England’s Long Term Plan target to detect 75% cancers at an early stage by 2028.
  • Cancer big data – using the data science expertise in Oxford by analysing large, complex data sets, in order to detect cancer earlier and treat it better.
  • Developments in immuno-oncology – building on existing immunology successes in Oxford, such as the COVID-19 vaccine, and applying these novel technologies to realise the long-term, curative benefits of immunotherapy.
  • Novel therapeutics and diagnostics - developing new therapies and methods that precisely target treatments more effectively, as well as improving the use of existing ones.

An additional £3 million in funding is dedicated specifically to studentships, to help train the next generation of cancer researchers and allow them pursue new and ambitious ideas.

Similar stories

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two National Institute for Health and Care Research (NIHR) Biomedical Research Centres (BRC).

The Department represented at the European Radiation Research Society annual conference

Researchers from the Department of Oncology attend the prestigious European Radiation Research Society (ERRS) in annual conference in Catania, Italy to present their research in Radiation Oncology.

Funding to research metformin’s ability to delay or prevent cancers driven by the mutated TP53 gene

A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin’s mechanism of action when taken as a preventative for mTP53-driven cancers.

Cancer patients remain at higher risk of severe COVID-19 disease despite third dose booster vaccine

A large population-level assessment reveals third dose COVID-19 vaccination is effective for most patients with cancer, but effectiveness is lower than in the general population, particularly in patients who have undergone recent chemotherapy and those with lymphoma.

Time-varying nature of clinical risk factors for pancreatic cancer may aid earlier diagnosis

Body mass index, blood tests, comorbidities and medication use are temporally associated with cancer risk in the three years before a pancreatic cancer diagnosis.